• BactiQuant’s revenue rose 36% year over year in January–September 2026, primarily driven by strong growth in recurring pharmaceutical revenue.
• Repaid the remaining kr. 7.2 million on its EIFO loan in the third quarter, reducing ongoing financing costs.
• An October private placement to existing shareholders, including management and the chairman, raised net proceeds of kr. 9 million, strengthening capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bactiquant A/S published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.